1.21
-0.01 (-0.82%)
| Previous Close | 1.22 |
| Volume | 362,983 |
| Price / Sales | 1.58 |
| Price / Book | 1.49 |
| 52 Weeks Range |
| Profit Margin | -156.48% |
| Operating Margin (TTM) | -247.80% |
| Diluted EPS (TTM) | -1.28 |
| Quarterly Revenue Growth (YOY) | -36.60% |
| Total Debt/Equity (MRQ) | 11.71% |
| Current Ratio (MRQ) | 2.56 |
| Operating Cash Flow (TTM) | -33.38 M |
| Levered Free Cash Flow (TTM) | -19.01 M |
| Return on Assets (TTM) | -37.21% |
| Return on Equity (TTM) | -107.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Spero Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.67 |
|
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.61% |
| % Held by Institutions | 23.25% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |